Table 1.
Baseline characteristics of the study participants
| Characteristic | INSIGHT (n=65) | EDITION (n=64) | P value |
|---|---|---|---|
| Age, yr | 63.7±8.8 | 64.5±10.2 | 0.658 |
| Range, yr | 36–77 | 22–86 | |
| Men/Women | 35/30 | 28/36 | 0.332 |
| Body weight, kg | 67.3±10.5 | 65.1±11.3 | 0.255 |
| Body mass index, kg/m2 | 25.5±2.8 | 25.1±3.0 | 0.415 |
| Range, kg/m2 | 20.6–33.3 | 19.5–35.0 | |
| Fasting plasma glucose, mmol/L | 7.8±2.1 | 8.0±2.3 | 0.704 |
| HbA1c, % | 8.4±0.7 | 8.4±0.8 | 0.758 |
| Prior basal insulin treatment | 59 (90.8) | 58 (90.6) | 0.999 |
| Total insulin dose, units/day | 26.9±13.0 | 25.9±12.9 | 0.651 |
| NIAHA | |||
| Metformin | 61 (93.8) | 51 (81.2) | 0.057 |
| Sulfonylurea | 35 (55.4) | 35 (54.7) | 0.999 |
| Glinides | 0 | 2 (3.1) | 0.469 |
| Thiazolidinediones | 0 | 1 (1.6) | 0.934 |
| DPP-4 inhibitors | 30 (46.2) | 31 (48.4) | 0.934 |
| GLP-1 receptor agonists | 3 (4.6) | 2 (3.1) | 0.999 |
| SGLT2 inhibitors | 5 (7.7) | 6 (9.4) | 0.979 |
| α-Glucosidase inhibitors | 1 (1.5) | 1 (1.6) | 0.999 |
| Hypertension | 44 (66.7) | 43 (67.2) | 0.999 |
| Hyperlipidemia | 52 (80.0) | 55 (85.9) | 0.508 |
Values are presented as mean±standard deviation or number (%).
INSIGHT, Implementing New Strategies with Insulin Glargine for Hyperglycemia Treatment; HbA1c, glycosylated hemoglobin; NIAHA, noninsulin antihyperglycemic agent; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; SGLT2, sodium-glucose cotransporter 2.